The first class of biologics comprises anti-tumor necrosis factor (anti-TNF) agents, including infliximab, adalimumab (ADM), etanercept and golimumab, which remain widely used in psoriasis, in addition to psoriatic arthritis and inflammatory bowel disease [2]. Here, TNF is linked to psoriasis.